Safety and Efficacy of Adalimumab Biosimilar in Psoriasis and Hidradenitis Suppurativa: A Clinical Experience
Saudi Medical Journal · 2026
DOI: 10.15537/1658-3175.8808 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Saudi Medical Journal, 2026. Verfasst von Raneem H Najjar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Eastern Health Cluster, Dammam, Kingdom of Saudi Arabia. Hauptthemen laut MEDLINE: Adalimumab, Biosimilar Pharmaceuticals, Hidradenitis Suppurativa, Psoriasis. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objectives
To evaluate the clinical experience, safety, and effectiveness of adalimumab biosimilars in patients with psoriasis and hidradenitis suppurativa.
Methods
We conducted a retrospective, single-center observational study between March and September 2024 using electronic medical records from King Abdulaziz Medical City and King Abdullah Specialized Children's Hospital, Riyadh, Saudi Arabia. Pediatric and adult patients with psoriasis or hidradenitis suppurativa who switched to adalimumab biosimilars between 2016 and 2022 were included. Variables included demographics, disease characteristics, prior therapies, biosimilar use, and adverse events.
Results
A total of 57 (93% adults; 50.9% female) patients were included. Obesity was present in 35.1%, and 6 (10.5%) patients had hidradenitis suppurativa. Plaque psoriasis was the most common subtype (72.5%), with psoriatic arthritis in 35.3%. Most patients (89.5%) switched to a biosimilar after treatment with the originator. The median dose and duration were 40 mg and 2–3 years, with high adherence (hidradenitis suppurativa 83.3%; psoriasis 90.2%). All patients with hidradenitis suppurativa improved, whereas 68.6% of patients with psoriasis responded, 19.6% showed no improvement, and 11.8% worsened. Adverse events were infrequent. Patients without obesity and those with prior response to adalimumab were more likely to benefit.
Conclusion
Adalimumab biosimilars demonstrate favorable efficacy and safety, particularly in prior responders. Patients with hidradenitis suppurativa showed consistent improvement. The low rate of adverse events and absence of new safety signals support safe clinical use. Further multicenter studies are needed to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Eastern Health Cluster, Dammam, Kingdom of Saudi Arabia.
- Department of Dermatology, King Abdul-Aziz Medical City, Riyadh, Kingdom of Saudi Arabia.
- College of Medicine, Princess Nourah Bint Abdulrahman University, Riyadh, Kingdom of Saudi Arabia.
- Consultant and Assistant Professor, King Abdul-Aziz Medical City, Riyadh, Kingdom of Saudi Arabia.
ORCID-Profile: Raneem H Najjar
Zitieren
APA
Najjar, R. H., Alrashid, S. O., Almahfouz, R. F., Alzahrani, H. T., Aleissa, M. Y., & Hakami, A. R. (2026). Safety and Efficacy of Adalimumab Biosimilar in Psoriasis and Hidradenitis Suppurativa: A Clinical Experience. Saudi Medical Journal. https://doi.org/10.15537/1658-3175.8808
Vancouver
Najjar RH, Alrashid SO, Almahfouz RF, Alzahrani HT, Aleissa MY, Hakami AR. Safety and Efficacy of Adalimumab Biosimilar in Psoriasis and Hidradenitis Suppurativa: A Clinical Experience. Saudi Medical Journal. 2026. doi:10.15537/1658-3175.8808
BibTeX
@article{Najjar2026,
author = {Najjar, Raneem H and Alrashid, Sarah O and Almahfouz, Rnda F and Alzahrani, Hadeel T and Aleissa, Majed Y and Hakami, Alanoud R},
title = {Safety and Efficacy of Adalimumab Biosimilar in Psoriasis and Hidradenitis Suppurativa: A Clinical Experience},
journal = {Saudi Medical Journal},
year = {2026},
doi = {10.15537/1658-3175.8808}
}
EUVIMED